Nordic Issuing

Ongoing case

Qlife Holding AB

Back to all cases

Qlife Holding AB

3 May - 31 May 2021Exercising of warrants TO 1

Qlife Aps was established in Copenhagen, Denmark by Thomas Warthoe, Peter Warthoe, Lars Bangsgaard and Ebbe Finding. The founders have spent the last 20 years in the IVD (In-Vitro Diagnostic) industry building small high-tech medical devices to partner with leading IVD companies and have gained solid know-how and experience in product development, regulatory approvals and business operations.

A professional board of directors was established in 2019 in connection with a capital injection of 5 MDKK from Danish Preseed Ventures, KMD Ventures and two Swedish business angels.
A pre-IPO was carried out in August 2019 and raised 18 MSEK for the company.

In 2019 the company obtained the ISO 13485:2016 certification, thus Qlife lives up to all requirements for manufacturing and selling in-vitro diagnostic analyzers and reagents. The first capsules for the Egoo System were CE marked for professional use early 2020.

The company has filed for patent protection for key elements of its technology. Today, the company organization consists of 39 people.

Qlife Holding AB was incorporated in October 2019, and is the sole owner of Qlife Aps, through a non-cash issue.

Qlife Holding AB finalised an IPO in february 2020 raising 55MSEK. The company is listed on Nasdaq, First North Growth Market, Stockholm as from March 2, 2020.

Read more on the company's website

The offer in summary

Subscription period: 3 May - 31 May 2021

Trading with TO 1: Until 27 May 2021

Subscription price: SEK 17.50

Capital raise (SEK): There are 4,472,600 outstanding warrants of series TO 1. Upon full exercise of all warrants of series TO 1, Invent Medic will receive a maximum of approximately SEK 39.1 million before issue costs.

There are 4,472,600 outstanding warrants of series TO 1. Holders of two (2) warrants of series TO 1 have the right through to subscribe for one (1) new share in Qlife Holding AB at a price of SEK 17.50 per share. Subscription with support of warrants of series TO 1 takes place during the period from 3 May 2021 up and including 31 May 2021. Subscription shall be made by immediate cash payment no later than on 31 May 2021.